The global Dengue Fever Treatment Market is predicted to generate a market value of US$ 877.82 Million in 2023 and a market value of US$ 5435.25 Million by 2023, with a CAGR of 20% from 2023 to 2033. From 2018 to 2022, the market for Dengue Fever Therapy grew at an 11% CAGR.
According to the World Health Organization, the incidence of dengue has grown dramatically over recent decades. Most of the reported cases are asymptomatic, mild or self-managed, and hence the actual number of infections are highly under-reported. Studies state that in 2022, and as of 19 December, 3,766,153 cases and 3582 deaths have been reported. The majority of cases have been reported from Brazil (2,182,229), Vietnam (325 604), Philippines (201,509), India (110,473) and Indonesia (94,355).
Get Full PDF Sample Copy of Latest Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16441
To enable effective treatment of dengue fever, market players are effectively leveraging strategic partnerships with major pharmaceutical corporations or research institutes, mergers & acquisitions and capacity expansion initiatives. Various startups are launching clinical trials to offer significant treatment for dengue. For instance, Singaporean startup StratifiCare provides a severe dengue prediction kit. It uses a set of proprietary biomarkers and a common laboratory assay platform. The solution is currently in the clinical development stage. The kit is able to deliver accuracy with 90% sensitivity and 97% specificity, in turn, reducing hospitalization costs.
Key Takeaways from the Market Study
- From 2018 to 2022, the Dengue Fever Treatment market grew at a CAGR of 11%.
- The global Dengue Fever Treatment market is expected to grow with a 20% CAGR during 2023 to 2033.
- As of 2033, the Dengue Fever Treatment Market is expected to reach US$ 5435.25 Million
- According to the FMI analysis, hospitals account for the largest market share.
- North America is expected to possess 25% market share for the Dengue Fever Treatment market.
- The Asia Pacific market is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering dengue fever treatments. Majority growth is likely to remain concentrated across the Asia-Pacific region, attributed to maximum dengue fever concentration as well as presence of reputed regional pharmaceutical giants.” says an FMI analyst
Last few days to get reports at discounted prices, offer expires soon!
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16441
Market Competition
Key players in the Dengue Fever Treatment market are Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi and Takeda Pharmaceutical Company Limited among other global players.
- In March 2021, Takeda Pharmaceutical Company Limited announced the approval of its TAK-003 dengue vaccine candidate by the European Medicines Agency (EMA), currently under investigation for preventing any outbreaks in individuals aged 4 to 60. The company also intends to apply for regulatory approvals in Argentina, Brazil, Columbia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka and Thailand through 2021.
More Insights Available
Asia Pacific is the largest dengue treatment market, owing to the high incidence of dengue fever in the region, particularly in countries such as India, Indonesia, and Thailand. The increasing healthcare expenditure and the growing awareness of the disease in the region are also expected to drive market growth.
For in-depth competitive analysis, Buy Now@ https://www.futuremarketinsights.com/checkout/16441
Key Segments Profiled in the Dengue Fever Treatment Industry Survey
Type:
- Drug
- Vaccines
Route of Administration:
- Oral
- Parenteral
End-User:
- Hospital
- Homecare
- Specialty Clinics
- Others
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time efficient research, and strategic recommendations with an objective to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis on key trends including competitive landscape, profit margin, and research development efforts.
About Future Market Insights, Inc.
Future Market Insights, Inc. is an ESOMAR-certified business consulting & market research firm, a member of the Greater New York Chamber of Commerce and is headquartered in Delaware, USA. A recipient of Clutch Leaders Award 2022 on account of high client score (4.9/5), we have been collaborating with global enterprises in their business transformation journey and helping them deliver on their business ambitions. 80% of the largest Forbes 1000 enterprises are our clients. We serve global clients across all leading & niche market segments across all major industries.
Contact:
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs
